Literature DB >> 9169438

Activation of the calcium-permeable cation channel CD20 by alpha subunits of the Gi protein.

M Kanzaki1, M A Lindorfer, J C Garrison, I Kojima.   

Abstract

When the calcium-permeable cation channel CD20 is expressed in Balb/c 3T3 cells, it is activated by insulin-like growth factor-I (IGF-I) via the IGF-I receptor (Kanzaki, M., Nie, L., Shibata, H., and Kojima, I. (1997) J. Biol. Chem. 272, 4964-4969). The present study was conducted to investigate the role of G proteins in the regulation of the CD20 channel. In the excised patch clamp mode, activation of the CD20 channel by IGF-I required GTP, Mg2+, and ATP in the bath solution, and removal of either GTP or ATP attenuated the activation. Non-hydrolyzable ATP could substitute for ATP, and guanyl-5'-yl thiophosphate blocked the activation of the channel by IGF-I. The CD20 channel was also activated by guanosine 5'-3-O-(thio)triphosphate, and ATP was not required for the activation. Addition of a preparation of Gi/Go holoprotein purified from bovine brain activated the CD20, and the beta-adrenergic receptor kinase peptide did not affect the number of channel openings induced by the G protein. The CD20 channel was stimulated by the GTP-bound form of recombinant Gi2 alpha subunit purified from Sf9 cells. The Gi3 alpha subunit was less effective, and the Gi1 alpha subunit had no effect. Purified recombinant beta1gamma2 subunits did not affect the activity of the channel. Finally, IGF-I-induced activation of CD20 was inhibited by an antibody against Gi2 alpha subunit. These findings indicate that the CD20 channel expressed in Balb/c 3T3 cells is activated by the IGF-I receptor via the alpha subunits of heterotrimeric G proteins.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9169438     DOI: 10.1074/jbc.272.23.14733

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

Review 1.  Calcium channels in lymphocytes.

Authors:  G Grafton; L Thwaite
Journal:  Immunology       Date:  2001-10       Impact factor: 7.397

Review 2.  CD20-mediated apoptosis: signalling through lipid rafts.

Authors:  Julie P Deans; Haidong Li; Maria J Polyak
Journal:  Immunology       Date:  2002-10       Impact factor: 7.397

Review 3.  Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies.

Authors:  Joshua S Davis; David Ferreira; Emma Paige; Craig Gedye; Michael Boyle
Journal:  Clin Microbiol Rev       Date:  2020-06-10       Impact factor: 26.132

4.  CD20+ T cells have a predominantly Tc1 effector memory phenotype and are expanded in the ascites of patients with ovarian cancer.

Authors:  Marco de Bruyn; Valerie R Wiersma; Maartje C A Wouters; Douwe F Samplonius; Harry G Klip; Wijnand Helfrich; Hans W Nijman; Paul Eggleton; Edwin Bremer
Journal:  Oncoimmunology       Date:  2015-03-19       Impact factor: 8.110

Review 5.  Are lupus animal models useful for understanding and developing new therapies for human SLE?

Authors:  Erica Moore; Chaim Putterman
Journal:  J Autoimmun       Date:  2020-06-11       Impact factor: 7.094

6.  CD20 deficiency in humans results in impaired T cell-independent antibody responses.

Authors:  Taco W Kuijpers; Richard J Bende; Paul A Baars; Annette Grummels; Ingrid A M Derks; Koert M Dolman; Tim Beaumont; Thomas F Tedder; Carel J M van Noesel; Eric Eldering; René A W van Lier
Journal:  J Clin Invest       Date:  2009-12-21       Impact factor: 14.808

Review 7.  Cancer stratification by molecular imaging.

Authors:  Justus Weber; Uwe Haberkorn; Walter Mier
Journal:  Int J Mol Sci       Date:  2015-03-04       Impact factor: 5.923

8.  CD20 is dispensable for B-cell receptor signaling but is required for proper actin polymerization, adhesion and migration of malignant B cells.

Authors:  Veronika Kozlova; Aneta Ledererova; Adriana Ladungova; Helena Peschelova; Pavlina Janovska; Aleksander Slusarczyk; Joanna Domagala; Pavel Kopcil; Viera Vakulova; Jan Oppelt; Vitezslav Bryja; Michael Doubek; Jiri Mayer; Sarka Pospisilova; Michal Smida
Journal:  PLoS One       Date:  2020-03-25       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.